Retinal vein occlusion
Conditions
Interventions
Intravitreal Conbercept group:Conbercept is injected monthly for three consecutive doses, followed by as-needed injections.
Intravitreal Conbercept combine with Dexamethasone group:The first month, Conbercept is injected, followed by Dexamethasone in the second month, followed by as-needed injections.
Sponsors
Eye and ENT hospital Fudan university
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent and willing to follow up at the time specified in the trial; 2. Age 18-80 years old, gender is not limited; 3. The target eye must meet the following requirements: (1) Clinically diagnosed retinal vein occlusion and untreated; (2) CMT greater than 300um; (3) Visual acuity of the affected eye is less than 20/40; Note: If the patient meets the inclusion criteria in both eyes, the target eye will be determined by the investigator from a medical point of view.
Exclusion criteria
Exclusion criteria: 1. History of vilituretomy surgery in the target eye; 2. Have uncontrolled hypertension (defined as blood pressure >=150/95 mmHg after antihypertensive drug treatment); 3. The patient has a history of glaucoma or secondary NVG; 4. Combined with diabetic retinopathy; 5. Active ocular infection (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis) or recurrent infection in the target eye or contralateral eye; 6. Presence of ocular tumor in the target eye; 7. Those who have allergic reactions or history of allergies to sodium fluorescein, allergies to therapeutic or diagnostic protein products, and allergies to >= two drugs and/or non-drug factors, or those who are suffering from allergic diseases; 8. Existing infectious diseases requiring oral, intramuscular or intravenous administration; 9. Have any uncontrollable clinical problems (such as: AIDS, malignant tumors, active hepatitis, renal failure, severe mental, neurological, cardiovascular, respiratory and other diseases, etc.); 10. Pregnant and lactating females (pregnancy in this test is defined as a positive urine pregnancy test); 11. Those who need to be excluded in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity;Central foveal thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Injection numbers;Complications; | — |
Countries
China
Contacts
Public ContactQing Chang;Tingting Jiang
Eye and ENT hospital Fudan university
Outcome results
None listed